Selected research
Industry Research
Montelukast Intermediate Industry Research Report 2026
Market perspective
The global Montelukast Intermediate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Montelukast Intermediate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Montelukast Intermediate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Montelukast Intermediate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Montelukast Intermediate include VIVAN Life Sciences, P.G. Shah & Co., Ortin Laboratories and Manus Aktteva Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Montelukast Intermediate market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Montelukast Intermediate Market by Company
VIVAN Life Sciences
P.G. Shah & Co.
Ortin Laboratories
Manus Aktteva Biopharma
Montelukast Intermediate Segment by Type
GMP
Non-GMP
Montelukast Intermediate Segment by Application
Bronchospasm
Urticaria
Asthma
Allergic Rhinitis
Montelukast Intermediate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Montelukast Intermediate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Montelukast Intermediate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Montelukast Intermediate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Montelukast Intermediate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Montelukast Intermediate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Montelukast Intermediate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- GMP
- Non-GMP
Applications
- Bronchospasm
- Urticaria
- Asthma
- Allergic Rhinitis
Companies covered
- VIVAN Life Sciences
- P.G. Shah & Co.
- Ortin Laboratories
- Manus Aktteva Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Montelukast Intermediate Market Size (2021-2032)
- 2.2.2 Global Montelukast Intermediate Sales (2021-2032)
- 2.2.3 Global Montelukast Intermediate Market Average Price (2021-2032)
- 2.3 Montelukast Intermediate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 GMP
- 2.3.3 Non-GMP
- 2.4 Montelukast Intermediate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bronchospasm
- 2.4.3 Urticaria
- 2.4.4 Asthma
- 2.4.5 Allergic Rhinitis
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Montelukast Intermediate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Montelukast Intermediate Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Montelukast Intermediate Revenue of Manufacturers (2021-2026)
- 3.4 Global Montelukast Intermediate Average Price by Manufacturers (2021-2026)
- 3.5 Global Montelukast Intermediate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Montelukast Intermediate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Montelukast Intermediate, Product Type & Application
- 3.8 Global Manufacturers of Montelukast Intermediate, Established Date
- 3.9 Global Montelukast Intermediate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 VIVAN Life Sciences
- 4.1.1 VIVAN Life Sciences Company Information
- 4.1.2 VIVAN Life Sciences Business Overview
- 4.1.3 VIVAN Life Sciences Montelukast Intermediate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 VIVAN Life Sciences Montelukast Intermediate Product Portfolio
- 4.1.5 VIVAN Life Sciences Recent Developments
- 4.2 P.G. Shah & Co.
- 4.2.1 P.G. Shah & Co. Company Information
- 4.2.2 P.G. Shah & Co. Business Overview
- 4.2.3 P.G. Shah & Co. Montelukast Intermediate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 P.G. Shah & Co. Montelukast Intermediate Product Portfolio
- 4.2.5 P.G. Shah & Co. Recent Developments
- 4.3 Ortin Laboratories
- 4.3.1 Ortin Laboratories Company Information
- 4.3.2 Ortin Laboratories Business Overview
- 4.3.3 Ortin Laboratories Montelukast Intermediate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ortin Laboratories Montelukast Intermediate Product Portfolio
- 4.3.5 Ortin Laboratories Recent Developments
- 4.4 Manus Aktteva Biopharma
- 4.4.1 Manus Aktteva Biopharma Company Information
- 4.4.2 Manus Aktteva Biopharma Business Overview
- 4.4.3 Manus Aktteva Biopharma Montelukast Intermediate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Manus Aktteva Biopharma Montelukast Intermediate Product Portfolio
- 4.4.5 Manus Aktteva Biopharma Recent Developments
5 Global Montelukast Intermediate Market Scenario by Region
- 5.1 Global Montelukast Intermediate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Montelukast Intermediate Sales by Region: 2021-2032
- 5.2.1 Global Montelukast Intermediate Sales by Region: 2021-2026
- 5.2.2 Global Montelukast Intermediate Sales by Region: 2027-2032
- 5.3 Global Montelukast Intermediate Revenue by Region: 2021-2032
- 5.3.1 Global Montelukast Intermediate Revenue by Region: 2021-2026
- 5.3.2 Global Montelukast Intermediate Revenue by Region: 2027-2032
- 5.4 North America Montelukast Intermediate Market Facts & Figures by Country
- 5.4.1 North America Montelukast Intermediate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Montelukast Intermediate Sales by Country (2021-2032)
- 5.4.3 North America Montelukast Intermediate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Montelukast Intermediate Market Facts & Figures by Country
- 5.5.1 Europe Montelukast Intermediate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Montelukast Intermediate Sales by Country (2021-2032)
- 5.5.3 Europe Montelukast Intermediate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Montelukast Intermediate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Montelukast Intermediate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Montelukast Intermediate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Montelukast Intermediate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Montelukast Intermediate Market Facts & Figures by Country
- 5.7.1 South America Montelukast Intermediate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Montelukast Intermediate Sales by Country (2021-2032)
- 5.7.3 South America Montelukast Intermediate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Montelukast Intermediate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Montelukast Intermediate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Montelukast Intermediate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Montelukast Intermediate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Montelukast Intermediate Sales by Type (2021-2032)
- 6.1.1 Global Montelukast Intermediate Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Montelukast Intermediate Sales Market Share by Type (2021-2032)
- 6.2 Global Montelukast Intermediate Revenue by Type (2021-2032)
- 6.2.1 Global Montelukast Intermediate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Montelukast Intermediate Revenue Market Share by Type (2021-2032)
- 6.3 Global Montelukast Intermediate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Montelukast Intermediate Sales by Application (2021-2032)
- 7.1.1 Global Montelukast Intermediate Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Montelukast Intermediate Sales Market Share by Application (2021-2032)
- 7.2 Global Montelukast Intermediate Revenue by Application (2021-2032)
- 7.2.1 Global Montelukast Intermediate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Montelukast Intermediate Revenue Market Share by Application (2021-2032)
- 7.3 Global Montelukast Intermediate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Montelukast Intermediate Value Chain Analysis
- 8.1.1 Montelukast Intermediate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Montelukast Intermediate Production Mode & Process
- 8.2 Montelukast Intermediate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Montelukast Intermediate Distributors
- 8.2.3 Montelukast Intermediate Customers
9 Global Montelukast Intermediate Analyzing Market Dynamics
- 9.1 Montelukast Intermediate Industry Trends
- 9.2 Montelukast Intermediate Industry Drivers
- 9.3 Montelukast Intermediate Industry Opportunities and Challenges
- 9.4 Montelukast Intermediate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst